Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4061244 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL7588597 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL5356889 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL8906942 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL4053845 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL23727498 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL3650896 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL8906883 | 1.00 | DUT (0.35) | DUTCYP1A2CYP2D6MAPTCYP2C9 | |
| SCHEMBL662237 | 0.98 | DUT (0.36) | DUT | |
| SCHEMBL1578618 | 0.94 | DUT (0.37) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048731-A1 | Hydroxylated Long-Chain Resveratrol Derivatives Useful as Neurotrophic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) (FR) | 2010-02-25 | — | — | US | disclosed |
| US-20100048731-A1 | Hydroxylated Long-Chain Resveratrol Derivatives Useful as Neurotrophic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) (FR) | 2010-02-25 | — | — | US | disclosed |
| EP-1991516-A2 | HYDROXYLATED LONG-CHAIN RESVERATROL DERIVATIVES USEFUL AS NEUROTROPHIC AGENTS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007099162-A2 | HYDROXYLATED LONG-CHAIN RESVERATROL DERIVATIVES USEFUL AS NEUROTROPHIC AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048731-A1 | Hydroxylated Long-Chain Resveratrol Derivatives Useful as Neurotrophic Agents | BDNF, NTRK2, NGF | DUT 4678/4885CYP1A2 2850/4885CYP2D6 2618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.